Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (ZNTL) has announced new equity grants under its 2022 Employment Inducement Incentive Award Plan. The company granted one newly hired employee 50,000 non-qualified stock options at an exercise price of $1.92 per share and 25,000 restricted stock units.
The stock options have a 10-year term with a four-year vesting schedule: 25% vesting after the first year and the remaining 75% vesting monthly over three years. The restricted stock units will vest in 25% increments annually over four years. Both grants are contingent on continued employment with Zentalis.
These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducement awards for individuals not previously employed by Zentalis, a clinical-stage biopharmaceutical company developing WEE1 inhibitor treatments for ovarian cancer and other tumor types.
Zentalis Pharmaceuticals (ZNTL) ha annunciato nuovi conferimenti di azioni nell'ambito del suo Piano di Incentivazione all'Occupazione 2022. L'azienda ha concesso a un nuovo dipendente 50.000 opzioni su azioni non qualificate a un prezzo di esercizio di $1,92 per azione e 25.000 unità di azioni vincolate.
Le opzioni su azioni hanno una durata di 10 anni con un programma di maturazione di quattro anni: il 25% matura dopo il primo anno e il restante 75% matura mensilmente per tre anni. Le unità di azioni vincolate matureranno in incrementi del 25% annualmente per quattro anni. Entrambi i conferimenti sono subordinati al mantenimento dell'impiego presso Zentalis.
Questi conferimenti sono stati effettuati in conformità con Nasdaq Listing Rule 5635(c)(4) come premi di incentivazione all'occupazione per individui non precedentemente impiegati da Zentalis, una compagnia biofarmaceutica in fase clinica che sviluppa trattamenti inibitori WEE1 per il cancro ovarico e altri tipi di tumori.
Zentalis Pharmaceuticals (ZNTL) ha anunciado nuevas concesiones de acciones bajo su Plan de Incentivos para el Empleo 2022. La empresa otorgó a un nuevo empleado 50.000 opciones sobre acciones no calificadas a un precio de ejercicio de $1.92 por acción y 25.000 unidades de acciones restringidas.
Las opciones sobre acciones tienen un plazo de 10 años con un calendario de adquisición de cuatro años: el 25% se adquiere después del primer año y el 75% restante se adquiere mensualmente durante tres años. Las unidades de acciones restringidas se adquirirán en incrementos del 25% anualmente durante cuatro años. Ambas concesiones están condicionadas a la continuidad del empleo en Zentalis.
Estas concesiones se realizaron de acuerdo con Nasdaq Listing Rule 5635(c)(4) como premios de incentivo para el empleo para individuos que no habían sido empleados previamente por Zentalis, una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos con inhibidores WEE1 para el cáncer de ovario y otros tipos de tumores.
젠탈리스 제약(ZNTL)은 2022년 고용 유인 인센티브 상여 계획에 따라 새로운 주식 보상을 발표했습니다. 회사는 새로 채용된 직원에게 50,000개의 비자격 주식 옵션을 주당 $1.92의 행사 가격으로 부여하고 25,000개의 제한 주식 유닛을 지급했습니다.
주식 옵션은 10년의 기간을 가지며 4년의 분할 일정에 따라 1년 후 25%가 분할되고 나머지 75%는 3년 동안 매달 분할됩니다. 제한 주식 유닛은 4년 동안 매년 25%씩 분할됩니다. 두 가지 보상은 젠탈리스에서 계속 근무하는 조건에 따라 이루어집니다.
이 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 젠탈리스에서 이전에 근무하지 않았던 개인을 위한 고용 유인 상여로 진행되었습니다. 젠탈리스는 난소암 및 기타 종양 유형에 대한 WEE1 억제제 치료제를 개발하는 임상 단계의 생명공학 회사입니다.
Zentalis Pharmaceuticals (ZNTL) a annoncé de nouvelles attributions d'actions dans le cadre de son Plan d'Incitation à l'Emploi 2022. L'entreprise a accordé à un nouvel employé 50 000 options d'achat d'actions non qualifiées à un prix d'exercice de 1,92 $ par action et 25 000 unités d'actions restreintes.
Les options d'achat d'actions ont une durée de 10 ans avec un calendrier d'acquisition de quatre ans : 25 % sont acquises après la première année et les 75 % restants sont acquis mensuellement pendant trois ans. Les unités d'actions restreintes seront acquises par tranches de 25 % chaque année pendant quatre ans. Les deux attributions sont conditionnées à la poursuite de l'emploi chez Zentalis.
Ces attributions ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4) en tant que primes d'incitation à l'emploi pour des personnes n'ayant pas été précédemment employées par Zentalis, une entreprise biopharmaceutique en phase clinique développant des traitements inhibiteurs WEE1 pour le cancer de l'ovaire et d'autres types de tumeurs.
Zentalis Pharmaceuticals (ZNTL) hat neue Aktienvergaben im Rahmen seines Beschäftigungsanreiz-Incentive-Preisplans 2022 angekündigt. Das Unternehmen hat einem neu eingestellten Mitarbeiter 50.000 nicht qualifizierte Aktienoptionen zu einem Ausübungspreis von 1,92 $ pro Aktie und 25.000 eingeschränkte Aktieneinheiten gewährt.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem Vesting-Plan von vier Jahren: 25% vesten nach dem ersten Jahr und die verbleibenden 75% vesten monatlich über drei Jahre. Die eingeschränkten Aktieneinheiten vesten in jährlichen 25%-Schritten über vier Jahre. Beide Vergaben sind an die Fortsetzung der Beschäftigung bei Zentalis gebunden.
Diese Vergaben wurden gemäß Nasdaq Listing Rule 5635(c)(4) als Beschäftigungsanreizpreise für Personen, die zuvor nicht bei Zentalis beschäftigt waren, vorgenommen, einem biopharmazeutischen Unternehmen in klinischer Phase, das WEE1-Inhibitor-Behandlungen für Eierstockkrebs und andere Tumorarten entwickelt.
- None.
- None.
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on March 3, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 50,000 shares of the Company’s common stock and 25,000 restricted stock units to one newly hired employee. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options and the restricted stock units are subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contacts:
Haibo Wang – Chief Business Officer
Ron Moldaver – Investor Relations
ir@zentalis.com
FAQ
What equity compensation did Zentalis (ZNTL) grant to its new employee in March 2025?
What is the vesting schedule for ZNTL's March 2025 stock option grants?
How will Zentalis's (ZNTL) restricted stock units vest under the March 2025 grant?
What is the exercise price of ZNTL's March 2025 stock option grants?
